OBJECTIVES: The aim of this study is to assess the economic impact of new strategies involving the administration of  triple therapy (PEG IFN , ribavirin and telaprevir or boceprevir) to naive patients with chronic hepatitis C (CHC). METHODS: economic results were evaluated  along a 30 – years time horizon. Seven health states were considered in our model: CHC genotype 1, sustained virologic response (SVR), compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation and death. The effectiveness of telaprevir in naïve patients was inferred from ADVANCE trial, whilst the effectiveness of boceprevir was inferred from the SPRINT 2 trial. Quality of life (QoL) scores were used to adjust the years gained by patients enrolled in the model. Resource consumption was estimated from the Italian SSN perspective. Costs and benefits were discounted at a rate of 3.5%. To map the uncertainty of the model resulting from the Bayesian analysis, a probabilistic sensitivity analysis was carried out. RESULTS: In both cases the ICER is likely to be under an hypothetical threshold of € 20.000 – 30.000. However, strategy which includes treatment with teelaprevir is proven to have a more favorable cost effectiveness ratio.(€ 12.000 vs € 14.000). In the case of telaprevir probability of being under the threshold of € 30.000/QALY is 100/, whist for Boceprevir probability is 70%. CONCLUSIONS: In general, the provision of either telaprevir and boceprevir was proved to be affordable compared to the standard of care.